Proactive Investors - Run By Investors For Investors

Genprex updates on positive results for its lung cancer drug Oncoprex

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner updates Proactive Investors on the latest developments with the Texas-based company's non-small cell lung cancer drug, including positive study results done in humanized mice.

Varner says the study of its lead drug Oncoprex at The University of Texas MD Anderson Cancer Center was completed in April after examining the effects of the tumor suppressor gene TUSC2 found in Oncoprex in combination with immunotherapy treatment.

 
View full GNPX profile View Profile

Genprex, Inc. Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use